Gastroparesis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injections), By Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, Others), By End-User (Hospitals, Pharmacies, Clinics) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Gastroparesis Drugs Market Size

The global gastroparesis drugs market size was valued at USD 5.71 billion in 2025 and is projected to grow from USD 5.98 billion in 2026 to USD 8.71 billion by 2034, registering a CAGR of 4.8% during the forecast period from 2026 to 2034. North America dominated the gastroparesis drugs market with a market share of 39.2% in 2025.

Gastroparesis is a condition marked by inadequate peristaltic contractions of the stomach muscles, resulting in digestive disturbances, including nausea, vomiting, abdominal discomfort, and difficulties in regulating blood sugar levels and absorbing nutrients. Gastroparesis is a condition that primarily affects individuals with type 1 and type 2 diabetes. Medications such as erythromycin, antiemetics, and Reglan are administered to treat gastroparesis.

The forecast year is expected to witness significant growth in the gastroparesis market due to the increasing frequency of idiopathic gastroparesis. Moreover, the rise in operations might lead to postoperative gastroparesis, which is expected to drive the expansion of the gastroparesis market. Furthermore, the increase in research and development efforts by producers to develop more sophisticated drugs for treating gastroparesis is expected to support the growth of the gastroparesis market. Furthermore, the rising prevalence of diabetes mellitus within the population will create further prospects for the expansion of the gastroparesis market in the future.

Drug Class Insights

The prokinetic agents segment dominated the market in 2023. Prokinetic medicines are a class of medications that enhance the contractions of the stomach muscles, hence improving gastric motility. They are commonly recommended to people suffering from gastroparesis, a condition that leads to symptoms such as nausea and vomiting while impeding digestion. Prokinetic medicines are essential in treating gastroparesis because they effectively target the root cause of the illness. Aside from their use in treating gastroparesis, these medications have also been examined for their efficacy and safety in critically ill patients receiving enteral nourishment. The studies have demonstrated favorable outcomes in lowering feeding intolerance in these patients.

Request Customizationto receive a tailored report.

Disease Type Insights

The diabetic gastroparesis segment held the largest share in 2023. The increase can be ascribed to the widespread occurrence of diabetes globally. Diabetic gastroparesis is a form of gastroparesis that arises as a consequence of diabetes, having a more pronounced impact on patients with diabetes. The Institute for Health Metrics and Evaluation (IHME) has announced a rise in worldwide diabetes diagnoses, projected to escalate from 529 million to 1.3 billion by 2050. Currently, diabetes has a worldwide prevalence rate of 6.1%, making it one of the top 10 leading causes of death and disability.

Additionally, an increase in the prevalence of diabetes can result in the development of diabetic gastroparesis. Pharmaceutical companies and researchers are currently prioritizing the development of medications that specifically target this form of gastroparesis, further contributing to the expansion of the diabetic gastroparesis segment in the market. In April 2022, Processa Pharmaceuticals commenced its Phase 2A trial for PCS12852, a promising therapeutic candidate for gastroparesis.

Postoperative gastroparesis, which is defined as a delay in the emptying of the stomach after abdominal surgery, presents considerable clinical difficulty. Postoperative gastroparesis, sometimes linked to treatments involving manipulation of the stomach or other organs, can result in extended hospital admissions, nutritional deficits, and reduced quality of life. The cause of this condition is either the interruption of neuronal connections or injury to the stomach muscles. Management generally entails conservative interventions, such as dietary adjustments and the use of prokinetic medications. If the condition is severe, surgical procedures like pyloroplasty may be considered. Prompt identification and care are crucial in minimizing complications and maximizing patient outcomes in cases of post-surgical gastroparesis.

End Users Insights

The hospital segment dominated the market in 2023. Hospitals possess the essential resources and medical proficiency to manage gastroparesis patients' intricate and diverse requirements, encompassing extreme instances that may necessitate surgical or specialized treatment. The comprehensive strategy and capacity to provide synchronized healthcare contribute to the hospital sector’s popularity.

The pharmacies segment is the fastest growing. The growth of the segment can be attributed to the convenient availability of pharmacies for patients buying gastroparesis pharmaceuticals and other relevant treatment medications, the ongoing expansion of retail pharmacy chains, and their emphasis on establishing an online presence.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global gastroparesis drugs market shareholder and is estimated to grow at a CAGR of 4.6% over the forecast period. The increase in the number of diabetes cases in this region can be mainly attributable to the high incidence of gastroparesis. Furthermore, the increasing prevalence of gastroparesis can be attributed to a significant number of individuals who are at risk of developing diabetes, as well as the presence of advantageous reimbursement policies and a rising level of awareness regarding this medical condition. The CDC’s June 2022 report indicates that around 96 million adults aged 18 and above in the United States have prediabetes, which accounts for 38.0% of the total adult population.

Moreover, the modern healthcare infrastructure and growing pharmaceutical industry in North America are crucial in facilitating the discovery, availability, and dissemination of drugs for gastroparesis. This resilient healthcare system enables prompt identification of illnesses, thorough provision of care to patients, and enhanced availability of medical interventions.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Gastroparesis Drugs Market Trends

Europe is anticipated to exhibit a CAGR of 4.7% over the forecast period. Europe is expected to experience significant growth in the forecast period due to the prevalence of gastroparesis and the rapid development of drug-delivery methods in the region. These methods include innovative drug delivery systems and controlled-release formulations, which provide a more convenient and effective treatment alternative. Furthermore, the significant emphasis placed by enterprises on patient-centric care and enhancing the quality of life for gastroparesis patients is expected to contribute positively to the region's growth.

The Asia-Pacific gastroparesis drugs market is experiencing a significant increase due to various influential factors. The increasing incidence of diabetes, an important predisposing factor for gastroparesis, in countries such as India and China is driving the need for efficient therapies. Moreover, the growing prevalence of Western diets and lifestyle practices, which result in obesity and metabolic problems, also contribute to the expanding number of patients.

Moreover, enhancements in healthcare infrastructure and the availability of medical services in nations around the area enable more accurate diagnosis and effective treatment of gastroparesis. Pharmaceutical companies acknowledge the unexplored market opportunity and allocate resources to research and develop innovative therapies for the Asian population. Furthermore, the increasing knowledge among medical practitioners and individuals on the ailment and its treatment is fueling the need for gastroparesis medications. Hence, these factors propelled the regional market growth.

List of Key and Emerging Players in Gastroparesis Drugs Market